On July 15, 2026, Defense Secretary Pete Hegseth ordered annual testosterone-deficiency screening for active-duty and reserve service members age 30 and older, folded into the periodic health assessment troops already complete each year (PBS NewsHour / AP, 2026). The screening is mandatory for that group. Any treatment that follows, including testosterone replacement therapy, is voluntary and left to the individual service member. Troops under 30 can request the test but are not required to take it.
The policy is the largest single expansion of testosterone screening in American history, and it has drawn sharp disagreement from the men's health specialists who treat low testosterone for a living. Understanding why requires separating what the policy does from what it claims it will accomplish.
What the Policy Actually Requires
Three things are worth pinning down, because early coverage blurred them together.
The screening is a blood test added to an existing annual requirement, not a new appointment or a new program. Service members 30 and older will have testosterone measured as part of the periodic health assessment they already sit for.
Treatment is optional. Hegseth was explicit that if a medical team recommends therapy, the decision belongs to the service member (PBS NewsHour / AP, 2026). Nobody is being ordered onto TRT.
The reach is narrower than the headlines suggest. The majority of active-duty personnel are 30 or younger, so the mandate applies to less than half the force (U.S. News, 2026).
Hegseth framed the initiative in readiness terms, saying it is "not about artificial enhancement" but about "restoring and optimizing your natural capabilities, protecting your longevity, and ensuring you have the biological foundation required to sustain the fight." Asked what specific conditions the policy addresses, the Pentagon pointed back to his remarks about keeping troops "strong, resilient and capable." The department did not identify the research or academic studies underpinning the decision (PBS NewsHour / AP, 2026).
Why Does the Medical Community Object to Routine Screening?
Because it runs against the standing guidelines from the two specialty societies that write them.
Both the American Urological Association and the Endocrine Society advise testing testosterone only in men who have symptoms suggesting deficiency, such as reduced libido, erectile dysfunction, fatigue, decreased muscle mass, or low bone density, or who have a high-risk condition known to cause low testosterone (Reuters via Army Times, 2026). Neither recommends population-wide screening of asymptomatic men.
Reuters contacted six men's health experts about the mandate. Five said they were puzzled by it and concerned it could lead to unnecessary or harmful treatment. Four said there was no solid evidence that screening every service member over 30 would improve combat readiness (Reuters via Army Times, 2026).
The concern is not that testosterone therapy does not work. It is that screening asymptomatic men produces a large pool of borderline results, and borderline results invite treatment the evidence does not support. "We hear from patients that when you treat low T, things like cognitive alertness and stamina improve," said Dr. Kevin McVary, a urologist on the medical advisory board of the telehealth platform Rugiet. "But the evidence is not concrete, and it comes from patients who were treated because they were symptomatic" (Reuters via Army Times, 2026).
Age 30 is also a contested threshold. Testosterone declines with age, but gradually and unevenly. "There is a population-level decline of 1% per year after ages 30 to 40 that accelerates as you get older," said Dr. Haleem Mohammed, chief medical officer of the men's health clinic network Gameday Health, noting the patterns are not the same for everyone. A 1% annual slope starting at 30 means a healthy 32-year-old is essentially indistinguishable from a healthy 30-year-old.
Then there is the measurement problem. Testosterone fluctuates substantially over the course of a day. Accurate readings require a morning draw after fasting, and guidelines call for two separate confirmed low results before a diagnosis (PBS NewsHour / AP, 2026). A single blood draw at whatever hour the appointment falls is not a diagnosis. The Pentagon has not published guidance on how abnormal results will be confirmed.
Hegseth cited Operator Syndrome as one target of the mandate, a condition first described in 2020 that bundles low testosterone with traumatic brain injury and sleep and metabolic dysregulation in special operations personnel. Dr. B. Christopher Frueh of the University of Hawaii, who led the team that named it, does not think the extrapolation holds. "These operators are at an extreme end of a spectrum," he said, citing their far higher exposure to blasts, jumps, and heavy weapons. Other troops might have elements of the syndrome, he allowed, "but should we be screening 100% of everybody? Maybe. I don't know" (Reuters via Army Times, 2026).
The Fertility Issue Nobody Should Skip
Every expert Reuters contacted raised the same point, and for a force whose median age is under 30, it is the most consequential risk in the policy.
Testosterone replacement suppresses the body's own production of the hormone. It shrinks the testes and reduces sperm counts, often dramatically. Both the AUA and Endocrine Society guidelines caution against TRT in men who intend to have children.
"Many in our armed forces are young men who are not done having their families," McVary said. "If you just dole out the testosterone, the testes will shrink. And you can't reliably count on them coming back" (Reuters via Army Times, 2026).
That last clause matters. Fertility usually recovers after stopping therapy, but not always, and not predictably. Any service member considering TRT who has not completed their family should have a fertility conversation, and likely a sperm banking conversation, before the first injection.
Other documented risks include blood thickening, prostate effects, acne, hair loss, breast tissue growth, and mood volatility.
What About the Heart Safety Question?
This is where the policy has its strongest evidentiary footing, with one caveat.
The TRAVERSE trial, led by Dr. Steven Nissen of the Cleveland Clinic, followed more than 5,200 men aged 45 to 80 who had low testosterone and elevated cardiovascular risk. It found no meaningful increase in major cardiovascular events, and the FDA subsequently removed the boxed warning about heart attack and stroke from testosterone labels (PBS NewsHour / AP, 2026).
The caveat is that TRAVERSE participants did show higher rates of atrial arrhythmia and bone fractures. Nissen himself flagged that these findings "may have implications for the military," which is a pointed observation about a population whose job involves physical impact and load-bearing (Reuters via Army Times, 2026). If you want the full picture on that fracture data, our guide to TRT and fracture risk breaks down what the TRAVERSE substudy found.
Separately, a series of NIH studies in older men found testosterone improved erectile function, libido, and other sexual measures, with a small effect on mood. It produced little or no improvement in fatigue, memory, or overall well-being (PBS NewsHour / AP, 2026). Those are real benefits. They are not the cognitive and stamina gains the readiness argument implies.
Is Broad Screening Ever Useful?
The policy is not without clinical defenders, and the strongest argument for it is not the readiness framing at all.
"Testosterone is one of the most useful blood tests we have to gauge health in men," Mohammed said. "Broader screening would identify many men with reversible causes and some with true deficiency. Both groups would benefit from clinician-guided care, whether that means correcting reversible causes or starting treatment when it is truly warranted" (Reuters via Army Times, 2026).
Low testosterone correlates with obesity, diabetes, depression, and cardiovascular disease. A low reading in a 34-year-old is often a signal about weight, sleep, or metabolic health rather than a prescription trigger. Frueh made the same point from the skeptical side: many younger service members with low readings could likely restore them through sleep, rest, and diet rather than hormone replacement. Used that way, as a marker that prompts investigation, broad screening could surface problems that would otherwise go unexamined for years.
Whether military medicine will use it that way, or default to writing prescriptions, is the open question. The Pentagon has not said.
